パートナーシップ
There is more Callavid® can do than we can pursue alone. Its patented leak-free design addresses the limitations that have constrained intravaginal delivery, and it is adaptable to hormones, locally-delivered antibiotics, live biotherapeutics, and treatments across oncology, menopause and infectious disease.
We work with leading biopharmaceutical companies to apply Callavid® to their pipelines: differentiating new assets, and extending the lifecycle of established ones, including off-patent therapeutics.
Merck
Calla Lily Clinical Care and Merck, a leading science and technology company, have entered a strategic collaboration to support the continued development of Callavid®. The collaboration represents the first industry partnership for our Callavid® technology.
Read more: Fierce on the Merck / Calla Lily Clinical Care partnership
Wellcome Leap
Calla Lily Clinical Care is one of the performers selected for Wellcome Leap’s Focused Antibiotics programme, a $50M initiative addressing antimicrobial resistance. We are evaluating Callavid® for targeted delivery of first-line UTI antibiotics, bypassing GI transit and first-pass metabolism.
Read more: Drug Discovery News on Calla Lily joining the Focused Antibiotics programme
National Institute for Health and Care Research
Calla Lily Clinical Care has secured over £1 million in funding from the NIHR through its Invention for Innovation (i4i) programme to advance our pioneering Callavid® technology addressing threatened miscarriage. NIHR support has taken Callavid® from concept to the clinic and represents crucial milestone in our mission to transform care for women experiencing threatened miscarriage.
University Hospitals Coventry and Warwickshire
Calla Lily Clinical Care is collaborating with UHCW NHS Trust on the FREEDOM trial, a clinical study of our progesterone delivery device, Callavid®. The NIHR-funded study is led by Professor Siobhan Quenby MBE, a leading expert in miscarriage and preterm birth, run collaboratively with the Trial Management Unit at UHCW. The trial is scheduled for completion in Q4 2026. (ISRCTN82163970; ClinicalTrials.gov NCT07136922)
Innovate UK
Calla Lily Clinical Care has been supported by Innovate UK – the UK government’s innovation agency – through both its SMART and BioMedical Catalyst funding programmes.
University of Warwick
Our partnership with the University of Warwick establishes a fully funded 4-year MSc/PhD program dedicated to advancing scientific research in vaginal microbiota and women's reproductive health. This collaborative research initiative explores the critical mechanisms by which vaginal microbiota protect against inflammation and pregnancy complications.
Queen Mary University of London
Our partnership with Queen Mary University of London advances critical research in women's reproductive health through an innovative PhD studentship focused on developing breakthrough solutions for bacterial vaginosis. Combining our clinical expertise with the university's leading bioengineering capabilities, we are developing a novel microbiome organ-chip model to explore probiotic interventions that could transform treatment approaches for a condition affecting 30% of reproductive-aged women.
UCL / UCL Consultants Ltd
We have established a multiyear partnership with UCL Consultants Ltd, working closely with Professor Catherine Tuleu's team to advance drug formulation technology for our Callavid® device.
パートナーシップや